Fulcrum Therapeutics Partners with Sanofi to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy
Shots:
- Fulcrum & Sanofi have signed a collaboration & license agreement to develop & commercialize losmapimod for facioscapulohumeral muscular dystrophy (FSHD), leveraging Sanofi’s global reach & Fulcrum’s expertise. Sanofi gained exclusive commercialization rights outside the US
- As per the agreement, Fulcrum will get $80M upfront, $975M regulatory & sales-based milestones & low-teens tiered escalating royalties based on annual net sales outside the US. Both will equally split future worldwide development costs
- Losmapimod is currently under P-III (REACH) evaluation for FSHD, the results of which are anticipated in Q4’24. Both will submit marketing applications across the US, EU, Japan & other regions based on P-III results
Ref: Fulcrum Therapeutics | Image: Fulcrum Therapeutics
Related News:- Fulcrum Seeks to Initiate the P-III (REACH) Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
